Recent Updates
Recently added Catalysts
PSNL Positive Sentiment

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Tuesday, July 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Personalis, Inc. has received UKCA marking for its NeXT Personal Dx test, allowing clinical use of its Minimal Residual Disease detection technology in Great Britain. This regulatory approval is a significant step for the company, enhancing its support for biopharma and increasing access to advanced genomic testing in the region.
Price reaction · baseline $15.04 (2026-07-13 close) · hit pre-market · clean, no other PSNL news in the window
day 0 close
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Achieved UKCA marking for NeXT Personal Dx test.
  • Enables clinical use of advanced MRD detection technology.
  • Expands access to precision oncology in Great Britain.

Full Press Release Details

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and Scotland.The UKCA marking confirms that the NeXT Personal Dx tes

Frequently Asked Questions

What is the significance of the UKCA marking?

The UKCA marking allows the clinical use of Personalis' NeXT Personal Dx test in Great Britain.

What technology does the NeXT Personal Dx test utilize?

The NeXT Personal Dx test utilizes ultrasensitive Minimal Residual Disease detection technology.

Which regions in Great Britain will benefit from this approval?

The approval covers England, Wales, and Scotland.

How does this approval impact biopharma support?

The UKCA marking enhances Personalis' support for biopharma by expanding access to precision oncology.

ShareAdd on Google
Tags: PSNL Viatris Investor Conferences Healthcare Personalis NeXT Personal MRD detection UKCA marking precision oncology
Last updated: Jul 14, 2026

Biotech snapshot

Cash runway
$233M liquidity · $7M/mo burn
~28 mo
Minimal dilution risk